Both drug-induced Parkinsonism (DIP) and tardive dyskinesia (TD) have been shown to be associated with lower health-related quality of life (HRQOL) in schizophrenia, but few studies have examined their relative impact.
Aims:
This study aimed to examine and compare the association of DIP and TD with HRQOL in schizophrenia.
Methods:
In total, 903 patients with schizophrenia were assessed on the Positive and Negative Syndrome Scale (PANSS), Simpson-Angus Scale (SAS), and Abnormal Involuntary Movement Scale (AIMS). EuroQoL five-dimensional (EQ-5D-5L) utility scores were derived from PANSS scores via a previously validated algorithm and used as a measure of HRQOL.
Results:
In total, 160 (17.7%) participants had only DIP, 119 (13.2%) had only TD, and 123 (13.6%) had both DIP and TD. HRQOL was lowest for participants with both DIP and TD, followed by only DIP group, only TD group, and highest in the group with neither condition. HRQOL scores differed significantly between the four groups, F(3, 892) = 13.724, p < 0.001, = 0.044). HRQOL of participants having only DIP or both DIP and TD was significantly lower than those having neither condition. There was no significant interaction between the presence of DIP and TD on the association with HRQOL.
Conclusions:
DIP was the main antipsychotic-induced movement disorder associated with a poorer HRQOL in patients with schizophrenia. Therefore, clinicians should focus on prevention, detection, and effective management of DIP to optimize HRQOL in patients with schizophrenia.
AbdinEChongSASeowE, et al. (2019) Mapping the Positive and Negative Syndrome Scale scores to EQ-5D-5L and SF-6D utility scores in patients with schizophrenia. Quality of Life Research28(1): 177–186.
2.
AdrianzénCArango-DávilaCAraujoDM, et al. (2010) Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: Post hoc analysis from a 3-year observational study. Human Psychopharmacology25(6): 439–447.
3.
ArangoCAdamiHSherrJD, et al. (1999) Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. The American Journal of Psychiatry156(7): 1097–1099.
4.
Ascher-SvanumHZhuBFariesD, et al. (2008) Tardive dyskinesia and the 3-year course of schizophrenia: Results from a large, prospective, naturalistic study. The Journal of Clinical Psychiatry69(10): 1580–1588.
5.
BarnesTR (2011) Evidence-based guidelines for the pharmacological treatment of schizophrenia: Recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology25(5): 567–620.
6.
BebbingtonPEAngermeyerMAzorinJM, et al. (2009) Side-effects of antipsychotic medication and health-related quality of life in schizophrenia. Acta psychiatrica Scandinavica. Supplementum438: 22–28.
7.
BobesJGarcia-PortillaMPBascaranMT, et al. (2007) Quality of life in schizophrenic patients. Dialogues in Clinical Neuroscience9(2): 215–226.
8.
BohlegaSAAl-FoghomNB (2013) Drug-induced Parkinson’s disease. A clinical review. Neurosciences18(3): 215–221.
9.
BrazierJEYangYTsuchiyaA, et al. (2010) A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. The European Journal of Health Economics11(2): 215–225.
10.
BriggsAWildDLeesM, et al. (2008) Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: Direct utility elicitation. Health and Quality of Life Outcomes6(1): 105.
11.
BrowneSRoeMLaneA, et al. (1996) Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatrica Scandinavica94(2): 118–124.
12.
CarbonMHsiehC-HKaneJM, et al. (2017) Tardive Dyskinesia prevalence in the period of second-generation antipsychotic use: A meta-analysis. The Journal of Clinical Psychiatry78(3): e264–e278.
13.
CaroffSN (2019) Overcoming barriers to effective management of tardive dyskinesia. Neuropsychiatric Disease and Treatment15: 785–794.
14.
ChanYH (2004) Biostatistics 201: Linear regression analysis. Singapore Medical Journal45(2): 55–61.
15.
ChongSATayJASubramaniamM, et al. (2009) Mortality rates among patients with schizophrenia and tardive dyskinesia. Journal of Clinical Psychopharmacology29(1): 5–8.
16.
ChouC-YMaM-CYangT-T (2014) Determinants of subjective health-related quality of life (HRQoL) for patients with schizophrenia. Schizophrenia Research154(1): 83–88.
17.
ConstantineRJTandonR (2007) Antipsychotics equivalent? CUtLASS renews the debate. Current Psychiatry6(2): 8.
18.
CornettEMNovitchMKayeAD, et al. (2017) Medication-induced Tardive Dyskinesia: A review and update. The Ochsner Journal17(2): 162–174.
19.
CraigBMRandK (2018) Choice defines QALYs: A US valuation of the EQ-5D-5L. Medical Care56(6): 529–536.
20.
D’SouzaRSHootenWM (2020) Extrapyramidal Symptoms. Treasure Island, FL: StatPearls Publishing.
21.
EmsleyRNiehausDJOosthuizenPP, et al. (2011) Subjective awareness of tardive dyskinesia and insight in schizophrenia. European Psychiatry26(5): 293–296.
22.
FirstMBSpitzerRLGibbonM, et al. (2002) Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P). New York: Biometric Research, New York State Psychiatric Institute.
GervinMBarnesTRE (2018) Assessment of drug-related movement disorders in schizophrenia. Advances in Psychiatric Treatment6(5): 332–341.
25.
HallidayJFarringtonSMacdonaldS, et al. (2002) Nithsdale Schizophrenia Surveys 23: Movement disorders. 20-year review. The British Journal of Psychiatry181: 422–427.
26.
HawleyCFinebergNRobertsA, et al. (2003) The use of the Simpson Angus Scale for the assessment of movement disorder: A training guide. International Journal of Psychiatry in Clinical Practice7(4): 349–2257.
27.
HerdmanMGudexCLloydA, et al. (2011) Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Quality of Life Research20(10): 1727–1736.
28.
HoferAMizunoYWartelsteinerF, et al. (2020) Quality of life in schizophrenia and bipolar disorder: The impact of symptomatic remission and resilience. European Psychiatry46: 42–47.
29.
HuangYPanLTengF, et al. (2017) A cross-sectional study on the characteristics of Tardive Dyskinesia in patients with chronic schizophrenia. Shanghai Archives of Psychiatry29(5): 295–303.
30.
JesteDVCaligiuriMPPaulsenJS, et al. (1995) Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry52(9): 756–765.
31.
JonesPBBarnesTREDaviesL, et al. (2006) Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry63(10): 1079–1087.
32.
KaySRFiszbeinAOplerLA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin13(2): 261–276.
33.
KimJH (2019) Multicollinearity and misleading statistical results. Korean Journal of Anesthesiology72(6): 558–569.
34.
KumsaAAgenagnewLAlemuB, et al. (2020) Psychotropic medications induced parkinsonism and akathisia in people attending follow-up treatment at Jimma Medical Center, Psychiatry Clinic. PLoS ONE15(7): e0235365.
35.
LarsenEBGerlachJ (1996) Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatrica Scandinavica93(5): 381–388.
36.
LeeJJiangJSimK, et al. (2010) The prevalence of tardive dyskinesia in Chinese Singaporean patients with schizophrenia: Revisited. Journal of Clinical Psychopharmacology30(3): 333–335.
37.
LeeJJiangJSimK, et al. (2011) Gender differences in Singaporean Chinese patients with schizophrenia. Asian Journal of Psychiatry4(1): 60–64.
38.
LehmanAFLiebermanJADixonLB, et al. (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. The American Journal of Psychiatry161(2 Suppl.): 1–56.
39.
LeuchtSHeresSKisslingW, et al. (2013) Pharmacological treatment of schizophrenia. Fortschritte der Neurologie Psychiatrie81(5): e1–e13.
40.
LimMWZLeeJ (2018) Determinants of health-related quality of life in schizophrenia: Beyond the medical model. Frontiers in Psychiatry9: 712.
41.
LongworthLYangYYoungT, et al. (2014) Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: A systematic review, statistical modelling and survey. Health Technology Assessment18(9): 1–224.
42.
LuytenJNaciHKnappM (2016) Economic evaluation of mental health interventions: An introduction to cost-utility analysis. Evidence-Based Mental Health19(2): 49–53.
43.
McEvoyJGandhiSKRizioAA, et al. (2019) Effect of tardive dyskinesia on quality of life in patients with bipolar disorder, major depressive disorder, and schizophrenia. Quality of Life Research28(12): 3303–3312.
44.
MacphersonRCollisR (1992) Tardive dyskinesia. Patients’ lack of awareness of movement disorder. British Journal of Psychiatry160: 110–112.
45.
MamoDCSweetRAKeshavanMS (1999) Managing antipsychotic-induced parkinsonism. Drug Safety20(3): 269–275.
46.
MeltzerHY (2004) What’s atypical about atypical antipsychotic drugs?Current Opinion in Pharmacology4(1): 53–57.
47.
ModestinJStephanPLErniT, et al. (2000) Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schizophrenia Research42(3): 223–230.
48.
MorgensternHGlazerWM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry50(9): 723–733.
49.
PatelKRCherianJGohilK, et al. (2014) Schizophrenia: Overview and treatment options. Pharmacy and Therapeutics39(9): 638–645.
50.
PonizovskyAMGrinshpoonALevavI, et al. (2003) Life satisfaction and suicidal attempts among persons with schizophrenia. Comprehensive Psychiatry44(6): 442–447.
51.
RitsnerMGibelAPerelroyzenG, et al. (2004) Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: A naturalistic comparative study. Journal of Clinical Psychopharmacology24(6): 582–591.
52.
RushAJ (2000) Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association.
53.
SaarniSIViertiöSPeräläJ, et al. (2018) Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. British Journal of Psychiatry197(5): 386–394.
54.
SatgharePAbdinEShahwanS, et al. (2020) Subjective quality of life and its associations among first episode psychosis patients in Singapore. International Journal of Environmental Research and Public Health17(1): 260.
55.
SchoolerNRKaneJM (1982) Research diagnoses for tardive dyskinesia. Archives of General Psychiatry39(4): 486–487.
56.
SeemanP (2002) Atypical antipsychotics: Mechanism of action. Canadian Journal of Psychiatry / Revue Canadienne De Psychiatrie47(1): 27–38.
57.
SianiCde PerettiCMillierA, et al. (2016) Predictive models to estimate utility from clinical questionnaires in schizophrenia: Findings from EuroSC. Quality of Life Research25(4): 925–934.
58.
SimpsonGMAngusJW (1970) A rating scale for extrapyramidal side effects. Acta psychiatrica Scandinavica. Supplementum212: 11–19.
59.
StrangePG (2001) Antipsychotic drugs: Importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacological Reviews53(1): 119–133.
60.
StrejilevichSAPalatnikAAvilaR, et al. (2005) Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Research133(2–3): 277–280.
61.
StroupTSGrayN (2018) Management of common adverse effects of antipsychotic medications. World Psychiatry17(3): 341–356.
62.
TandonRNasrallahHAKeshavanMS (2009) Schizophrenia, “just the facts” 4. Clinical features and conceptualization. Schizophrenia Research110(1–3): 1–23.
63.
TarsyDBaldessariniRJ (2006) Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?Movement Disorders21(5): 589–598.
64.
van HartenPNMatroosGEHoekHW, et al. (1996) The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I. Schizophrenia Research19(2–3): 195–203.
65.
WalnOJankovicJ (2013) An update on tardive dyskinesia: From phenomenology to treatment. Tremor and Other Hyperkinetic Movements3: tre-03-161-4138-1.
66.
WardKMCitromeL (2018) Antipsychotic-related movement disorders: Drug-induced Parkinsonism vs. Tardive Dyskinesia—Key differences in pathophysiology and clinical management. Neurology and Therapy7(2): 233–248.
67.
WeirCBJanA (2021) BMI Classification Percentile and Cut Off Points. Treasure Island, FL: Statpearls Publishing LLC.
68.
WoodsSW (2003) Chlorpromazine equivalent doses for the newer atypical antipsychotics. The Journal of Clinical Psychiatry64(6): 663–667.
69.
WoodsSWMorgensternHSaksaJR, et al. (2010) Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: A prospective cohort study. The Journal of Clinical Psychiatry71(4): 463–474.
70.
WuJQChenDCXiuMH, et al. (2013) Tardive dyskinesia is associated with greater cognitive impairment in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry46: 71–77.
71.
XiangYTWengYZLeungCM, et al. (2008) Socio-demographic and clinical correlates of lifetime suicide attempts and their impact on quality of life in Chinese schizophrenia patients. Journal of Psychiatric Research42(6): 495–502.
72.
YassaR (1989) Functional impairment in tardive dyskinesia: Medical and psychosocial dimensions. Acta Psychiatrica Scandinavica80(1): 64–67.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
